Accordingly, a selective HO-1 inhibitor was studied in a widely accepted animal model of AD (APPswe/PS1∆E9 double-transgenic mouse), inducing amelioration of symptoms after treatment [117]. This evidence concerns the gene HMOX1 and Alzheimer disease.